Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

dy, the company's A-beta antibody holds the potential for slowing down the progression of Alzheimer's disease. Enrollment began in May 2009 in two multi-national Phase III registration studies - EXPEDITION and EXPEDITION 2. Each study will enroll 1,000 subjects for an 18-month treatment duration.
  • mGlu 2/3 Prodrug - An open-label study continues for this potential schizophrenia compound currently in Phase II of clinical development. The company plans to proceed with further efficacy testing, and anticipates initiating two large studies in the first half of 2010.
  • iGluR5 Receptor Antagonist - Work on this pain compound continues to progress. Phase II studies began in osteoarthritis and diabetic peripheral neuropathic pain in the second quarter of 2009. Other pain indications are also being considered, including migraine prevention.
  • Insomnia Compound LY2624803 - A Phase II study is ongoing and recently completed enrollment ahead of plan. Results are expected in the first half of 2010.
  • IL-17 antibody - This molecule continues to be studied for its potential in rheumatoid arthritis (RA) and in other autoimmune disorders. In August, a Phase IIb trial for IL-17 was initiated in RA designed to further elucidate the molecule's safety and efficacy and to establish a dosing regimen for Phase III trials. This trial is expected to conclude in early 2011.
  • BAFF antagonist - Enrollment was recently completed in two Phase II clinical trials for rheumatoid arthritis and, earlier this year, a Phase II study was initiated in patients with relapsing-remitting multiple sclerosis.
  • Oncology

    With the acquisition of ImClone and the progression of its own pipeline, Lilly is well along the way to building an oncology powerhouse. Within the oncology business unit, Lilly's three key cancer medicines - Alimta®, Gemzar® and Erbitux® - account for 14 percent of the
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
    4. Lilly Receives NCQA Design Certification for Depression Care Management Program
    5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
    6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
    7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
    8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
    9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
    10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
    11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... TAIPEI , Sept. 1, 2015 ... 2,500 employees, SHL Group has rapidly reached 3,000 ... yet rapid growth in the injectable drug delivery ... A global leader in the design ... SHL offers innovative designs, robust manufacturing capabilities, a ...
    (Date:9/1/2015)... Sept. 1, 2015 Pressure BioSciences, Inc. ... in the development and sale of broadly enabling, ... the worldwide life sciences industry, today announced the ... the Company,s PCT Platform could play a significant ... This role is based on PCT,s unique ability ...
    (Date:9/1/2015)...  Abbott (NYSE: ABT ) announced today positive one-year ... comparing the safety and effectiveness of Abbott,s fully dissolving ... market-leading, permanent drug eluting stent. The trial was conducted ... and enrolled 400 people with coronary artery disease, the ... be featured at a late-breaking session today at ESC ...
    Breaking Medicine Technology:SHL Group Reaches Major Milestone of 3000 Employees 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
    ... , NEW YORK, November 17 ... biomarkers will help identify and monitor patients at risk,of developing ... are,cared for in prenatal clinics around the world. , ... highly-respected National,Institute of Child and Human Development of the National ...
    ... , NEW YORK, Nov. 17 ... Street is the first laser hair removal center in New ... system by Cynosure, Inc., a leading developer and manufacturer of ... Elite MPX, which incorporates Cynosure,s patented MultiPlex sequencing technology, is ...
    Cached Medicine Technology:New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 2New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 3Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2
    (Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound ... a wound to remove exudates, fluid, and infectious materials to prepare the wound ... devices, disposable devices, and canisters, etc.) is projected to expand continuously through 2021. ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... has announced that Edge Information Management has been granted continued accreditation ... Credentialing Council (BSCC). , ÔÇťAchieving and maintaining this accreditation takes the ...
    (Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... remote real-time monitoring and analysis of pet vital signs and activity, today announced ... is one of the most popular and widely-adopted veterinary hospital Practice Management Software ...
    (Date:9/1/2015)... Francisco, Calif. (PRWEB) , ... September 01, 2015 ... ... to corporations, law firms and government entities, announced today that it has hired ... Senior Discovery Consultant. In this capacity, Sanderson will be responsible for establishing ...
    Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
    ... mediator in the blood that influences immune cell migration ... between the build-up and breakdown of bones in the ... bone, may provide a new target for scientists developing ... and rheumatoid arthritis. , The study comes ...
    ... WASHINGTON, Feb. 7 As the military deals with ... of Veterans Affairs Eric K. Shinseki reminded Veterans and ... has an extensive array of services to help Veterans ... take advantage of our suicide-prevention program," said Shinseki. "Help ...
    ... women who got injections report reduced pain and ... first evidence that gene therapy can ease symptoms in ... American and German researchers. , The study included ... interleukin-1 receptor antagonist (IL-1Ra) gene into the women,s affected ...
    ... CVD ) today announced that it will present at ... 2009 at 3:30 p.m. (ET). Investors may access a ... In order to register and download any necessary software, please ... Princeton, New Jersey, is one of the world,s largest and ...
    ... World Heart Corporation,("WorldHeart", Nasdaq: WHRT ), ... has appointed John Alexander ("Alex") Martin as,President and CEO. ... the Board of,Directors. Mr. Martin joins WorldHeart from ... Region and Corporate Vice President since,2004. Previously, Alex ...
    ... the same as supplement available in U.S., study says , , ... and 6 sulfate (CS) appears to slow the worsening and ease ... , The European study, published in the February issue ... CS over two years lost less joint space -- with few ...
    Cached Medicine News:Health News:Scientists discover key factor in controlling the breakdown of bone 2Health News:Scientists discover key factor in controlling the breakdown of bone 3Health News:VA Suicide Prevention Hotline Credited with 2,600 'Saves' 2Health News:Gene Therapy May Ease Rheumatoid Arthritis 2Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3
    RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
    For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
    ... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
    ... (cTnI) has been useful in the differential ... (ED) with chest pain. 18-20 ... levels of sensitive and specific biomarkers, such ... creatine kinase (CK-MB), and myoglobin, are increased ...
    Medicine Products: